S&CO Inc. Sells 1,370 Shares of Merck & Co. (MRK)

S&CO Inc. decreased its holdings in shares of Merck & Co. (NYSE:MRK) by 0.4% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 386,795 shares of the company’s stock after selling 1,370 shares during the quarter. Merck & Co. comprises about 2.7% of S&CO Inc.’s portfolio, making the stock its 8th biggest holding. S&CO Inc.’s holdings in Merck & Co. were worth $21,069,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. Franklin Resources Inc. boosted its position in shares of Merck & Co. by 58.4% during the 4th quarter. Franklin Resources Inc. now owns 43,221,157 shares of the company’s stock valued at $2,432,154,000 after acquiring an additional 15,932,771 shares during the last quarter. American International Group Inc. boosted its position in shares of Merck & Co. by 992.8% during the 4th quarter. American International Group Inc. now owns 9,152,305 shares of the company’s stock valued at $515,000,000 after acquiring an additional 8,314,765 shares during the last quarter. Mackenzie Financial Corp boosted its position in shares of Merck & Co. by 33,282.9% during the 4th quarter. Mackenzie Financial Corp now owns 5,941,154 shares of the company’s stock valued at $334,309,000 after acquiring an additional 5,923,357 shares during the last quarter. Janus Henderson Group PLC boosted its position in shares of Merck & Co. by 172.3% during the 3rd quarter. Janus Henderson Group PLC now owns 6,705,564 shares of the company’s stock valued at $429,347,000 after acquiring an additional 4,243,246 shares during the last quarter. Finally, Capital International Investors boosted its position in shares of Merck & Co. by 55.3% during the 3rd quarter. Capital International Investors now owns 9,623,382 shares of the company’s stock valued at $616,185,000 after acquiring an additional 3,428,400 shares during the last quarter. 74.87% of the stock is owned by institutional investors and hedge funds.

Several research analysts have recently weighed in on the stock. Leerink Swann lowered their price target on shares of Merck & Co. from $67.00 to $66.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 14th. Credit Suisse Group lowered their price target on shares of Merck & Co. from $67.00 to $66.00 and set an “outperform” rating on the stock in a research report on Monday, February 5th. ValuEngine cut shares of Merck & Co. from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Zacks Investment Research cut shares of Merck & Co. from a “buy” rating to a “hold” rating in a research report on Wednesday, May 16th. Finally, BMO Capital Markets set a $65.00 price target on shares of Merck & Co. and gave the company an “outperform” rating in a research report on Tuesday, February 13th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have given a buy rating to the company. Merck & Co. currently has an average rating of “Buy” and a consensus price target of $65.87.

In other Merck & Co. news, EVP Julie L. Gerberding sold 9,972 shares of the company’s stock in a transaction dated Tuesday, May 15th. The shares were sold at an average price of $59.66, for a total value of $594,929.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Weir Mirian M. Graddick sold 24,000 shares of the stock in a transaction dated Monday, April 16th. The stock was sold at an average price of $58.00, for a total transaction of $1,392,000.00. The disclosure for this sale can be found here. Corporate insiders own 0.32% of the company’s stock.

NYSE MRK opened at $59.14 on Monday. Merck & Co. has a 12 month low of $52.83 and a 12 month high of $66.41. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.10 and a current ratio of 1.42. The stock has a market capitalization of $159.45 billion, a price-to-earnings ratio of 14.86, a P/E/G ratio of 2.25 and a beta of 0.76.

Merck & Co. (NYSE:MRK) last posted its earnings results on Tuesday, May 1st. The company reported $1.05 EPS for the quarter, beating the Zacks’ consensus estimate of $1.00 by $0.05. Merck & Co. had a net margin of 4.31% and a return on equity of 30.93%. The company had revenue of $10.04 billion for the quarter, compared to analysts’ expectations of $10.09 billion. During the same quarter in the prior year, the company posted $0.88 earnings per share. Merck & Co.’s revenue for the quarter was up 6.4% compared to the same quarter last year. analysts predict that Merck & Co. will post 4.23 EPS for the current fiscal year.

Merck & Co. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Institutional Ownership by Quarter for Merck & Co. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply